FrancophonIA/ELRC3.0 huggingface dataset:
English: Other information about Ebilfumin
Estonian: Muu teave Ebilfumini kohta
English: As for all medicines, data on the use of Ebilfumin are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Ebilfumini kasutamise kohta pidevat järelevalvet.
English: What is Ebilfumin and what is it used for?
Estonian: Mis on Ebilfumin ja milleks seda kasutatakse?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Ebilfumin has been shown to have comparable quality and to be bioequivalent to Tamiflu.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Ebilfumin võrreldav kvaliteet ja bioekvivalentsus Tamifluga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ebilfumin have been included in the summary of product characteristics and the package leaflet.
Estonian: Ebilfumini ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Because Ebilfumin is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Ebilfumin on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Ebilfumin is an antiviral medicine used to treat or prevent influenza (flu).
Estonian: Ebilfumin on viirusvastane ravim, mida kasutatakse gripi raviks või ennetamiseks.
English: This means that Ebilfumin contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Tamiflu.
Estonian: See tähendab, et Ebilfumin sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Tamiflu, millel juba on ELis müügiluba.
English: Oseltamivir works on the neuraminidases of both influenza-A (the most common type) and influenza-B viruses.
Estonian: Oseltamiviir toimib nii Atüüpi gripiviiruse (kõige tavalisem tüüp) kui ka B-tüüpi gripiviiruse neuraminidaaside suhtes.
English: As for every medicine, the company provided studies on the quality of Ebilfumin.
Estonian: Nagu iga ravimi korral, esitas ettevõte Ebilfumini kvaliteedi uuringud.
English: The usual dose for adults and children weighing more than 40 kg is 75 mg given twice a day for 5 days.
Estonian: Täiskasvanutel ja üle 40 kg kaaluvatel lastel on tavaannus 75 mg, mida antakse 2 korda ööpäevas 5 päeva jooksul.
English: Therefore, the Agency's view was that, as for Tamiflu, the benefit of Ebilfumin outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Tamiflu korral, ületab Ebilfumini kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: The usual dose for adults and children weighing more than 40 kg is 75 mg given once a day for 10 days after contact with an infected person.
Estonian: Täiskasvanutel ja üle 40 kg kaaluvatel lastel on tavaannus 75 mg, mida antakse 1 kord ööpäevas vähemalt 10 päeva jooksul pärast kokkupuudet nakatunud isikuga.
English: Ebilfumin contains the active substance oseltamivir.
Estonian: Ebilfumin sisaldab toimeainena oseltamiviiri.
English: In the treatment of flu, Ebilfumin must be started within two days of the onset of symptoms.
Estonian: Gripi ravimisel peab Ebilfumini kasutamist alustama kahe ööpäeva jooksul alates sümptomite tekkest.
English: This is generally done on a caseby-case basis.
Estonian: Üldiselt otsustab arst seda igal üksikjuhul eraldi.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Tamiflu, and do not need to be repeated for Ebilfumin.
Estonian: Võrdlusravimiga Tamiflu on juba tehtud toimeaine heakskiidetud näidustuste kasulikkuse ja riski uuringud ning neid ei ole vaja Ebilfuminiga korrata.
English: The active substance in Ebilfumin, oseltamivir, acts on the flu virus, blocking some of the enzymes on its surface known as neuraminidases.
Estonian: Ebilfumini toimeaine oseltamiviir toimib gripiviiruse suhtes, blokeerides viiruse pinnal teatud ensüümid (neuraminidaasid).
English: For children who weigh less than 40 kg, the dose is calculated according to the child's weight.
Estonian: Alla 40 kg laste annus arvutatakse lapse kehamassi järgi.
English: • To treat flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is circulating in the community;
Estonian: • Gripi raviks tohib ravimit kasutada gripisümptomitega täiskasvanutel ja lastel (sh õigeaegsetel vastsündinutel), kui kogukonnas levib gripiviirus.
English: An overview of Ebilfumin and why it is authorised in the EU
Estonian: Ülevaade ravimist Ebilfumin ja ELis müügiloa väljastamise põhjendus
English: How does Ebilfumin work?
Estonian: Kuidas Ebilfumin toimib?
English: • To prevent flu, it can be used in adults and children over 1 year of age who have been in contact with someone who has flu and flu is circulating in the community.
Estonian: • Gripi ennetamiseks tohib ravimit kasutada täiskasvanutel ja vähemalt 1-aastastel gripipatsiendiga kokku puutunud lastel, kui kogukonnas levib gripiviirus.
English: During a flu pandemic, Ebilfumin can also be used to prevent flu in babies below 1 year of age.
Estonian: Ebilfumini kasutada gripi raviks või ennetamiseks ka alla 1-aastastel imikutel.
English: How is Ebilfumin used?
Estonian: Kuidas Ebilfumini kasutatakse?
English: How has Ebilfumin been studied?
Estonian: Kuidas Ebilfumini uuriti?
English: In the prevention of flu, Ebilfumin must be started within two days of contact with someone who has flu.
Estonian: Gripi ennetamisel peab Ebilfumini kasutamist alustama kahe ööpäeva jooksul alates kokkupuutest gripipatsiendiga.
English: It is a ‘generic medicine'.
Estonian: Ebilfumin on geneeriline ravim.
English: What are the benefits and risks of Ebilfumin?
Estonian: Milles seisneb Ebilfumini kasulikkus ja mis riskid ravimiga kaasnevad?
English: The recommended dose is 800 mg on days 1 and 8 of each 3-week cycle.
Estonian: Soovitatav annus on 800 mg iga 3-nädalase tsükli 1. ja 8. päeval.
English: A risk management plan has been developed to ensure that Portrazza is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Portrazza võimalikult ohutu kasutamine.
English: Other information about Portrazza
Estonian: Muu teave Portrazza kohta
English: The full EPAR and risk management plan summary for Portrazza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Portrazza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Portrazza?
Estonian: Mis meetmed võetakse, et tagada Portrazza ohutu ja efektiivne kasutamine?
English: Portrazza must not be used in patients who have had a severe or life-threatening reaction to any of the ingredients of the medicine.
Estonian: Portrazzat ei tohi kasutada patsiendid, kellel on olnud selle ravimi mis tahes koostisaine suhtes raske või eluohtlik reaktsioon.
English: What is Portrazza and what is it used for?
Estonian: Mis on Portrazza ja milleks seda kasutatakse?
English: Portrazza necitumumab
Estonian: Portrazza netsitumumaab
English: Why is Portrazza approved?
Estonian: Miks Portrazza heaks kiideti?
English: Most of the patients (95%) had cancer cells with EGFR.
Estonian: Enamikul patsientidest (95%) esines vähirakkudes EGFRi.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Portrazza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee järeldas, et Portrazza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The most common serious side effects are severe skin reactions (6% of patients) and blood clots (4% of patients).
Estonian: Kõige sagedamad rasked kõrvalnähud on rasked nahareaktsioonid (6% patsientidest) ja trombid (4% patsientidest).
English: The most common side effects with Portrazza (which may affect more than 1 in 10 people) are skin reactions, vomiting, stomatitis (inflammation of the lining of the mouth), fever, weight loss and low blood measurements of various minerals (magnesium, calcium, phosphate and potassium).
Estonian: Portrazza kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nahareaktsioonid, oksendamine, stomatiit (suu limaskesta põletik), palavik, kaalulangus ja mitme mineraalaine (magneesium, kaltsium, fosfaat ja kaalium) sisalduse vähenemine veres.
English: EGFR normally controls the growth and division of cells, but in cancer cells EGFR is often overactive, causing them to divide uncontrollably.
Estonian: Normaalselt reguleerib EGFR rakkude kasvu ja jagunemist, kuid vähirakkudes on EGFR sageli liiga aktiivne, põhjustades nende vohamist.
English: It is not intended to provide practical advice on how to use Portrazza.
Estonian: Hindamisaruandes ei anta Portrazza kasutamise praktilisi nõuandeid.
English: The risk of reactions can be reduced by adjusting the dose or infusion rate or by using preventive medicines.
Estonian: Reaktsiooniriski saab vähendada annust või infusioonikiirust kohandades või ennetavate ravimitega.
English: During infusions, resources should be available to deal with reactions that may occur.
Estonian: Infusioonide ajal peavad olema käepärast vahendid võimalike reaktsioonide raviks.
English: By attaching to and blocking EGFR, necitumumab helps to reduce the growth and spread of the cancer.
Estonian: EGFR-iga seondudes ja seda blokeerides aitab netsitumumaab aeglustada vähi kasvu ja levikut.
English: In this study, patients treated with Portrazza in addition to chemotherapy lived on average 1.6 months longer than those treated with chemotherapy alone (11.5 months versus 9.9 months).
Estonian: Selles uuringus oli patsientide elumus peale keemiaravi ka Portrazzat kasutanute uuringurühmas keskmiselt 1,6 kuud pikem (11,5 kuud) kui ainult keemiaravi rühmas (9,9 kuud).
English: What are the risks associated with Portrazza?
Estonian: Mis riskid Portrazzaga kaasnevad?
English: A main study of 1,093 patients with advanced squamous non-small cell lung cancer showed that adding Portrazza to gemcitabine and cisplatin chemotherapy can lead to a modest improvement in survival.
Estonian: Põhiuuringus, kus osales kaugelearenenud lamerakulise mitteväikerakk-kopsuvähiga 1093 patsienti, ilmnes, et Portrazza lisamine gemtsitabiini ja tsisplatiini sisaldavale keemiaravile võib mõnevõrra pikendada patsientide elumust.
English: For the first 6 cycles, Portrazza is given together with gemcitabine and cisplatin chemotherapy, after which it is given on its own for as long the disease remains stable and the patient can tolerate it.
Estonian: Esimese 6 tsükli jooksul manustatakse Portrazzat koos gemtsitabiini ja tsisplatiini sisaldava keemiaraviga, seejärel manustatakse seda monoteraapiana nii kaua, kuni haigus püsib stabiilsena ja patsient talub ravimit.
English: In case of a severe infusion or skin reaction, treatment may have to be stopped permanently.
Estonian: Raske infusioonivõi nahareaktsiooni korral võib olla vaja ravi lõplikult katkestada.
English: For the full list of all side effects reported with Portrazza, see the package leaflet.
Estonian: Portrazza kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Portrazza, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Portrazza omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In addition, the company that markets the medicine will provide doctors with educational material with information on risk of blood clots and on the small number of cardiac arrest cases seen in studies.
Estonian: Lisaks annab ravimit turustav ettevõte arstidele teabematerjalid, milles selgitatakse ravimiga kaasnevat trombiriski ja uuringutes täheldatud südameseiskuse väikest arvu juhtumeid.
English: Portrazza is only used in adults whose cancer cells have a specific protein (EGFR) on their surface and it is used together with gemcitabine and cisplatin chemotherapy.
Estonian: Portrazzat tohivad kasutada ainult täiskasvanud, kelle vähirakkude pinnal esineb teatud valku (EGFR), ning seda kasutatakse koos gemtsitabiini ja tsisplatiini sisaldava keemiaraviga.
English: For practical information about using Portrazza, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Portrazza kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Portrazza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Portrazzaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Portrazza have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Portrazza kasulikkus?
English: This is a summary of the European public assessment report (EPAR) for Portrazza.
Estonian: See on ravimi Portrazza Euroopa avaliku hindamisaruande kokkuvõte.
English: How is Portrazza used?
Estonian: Kuidas Portrazzat kasutatakse?
English: In the main study, adding Portrazza to gemcitabine and cisplatin chemotherapy improved survival by a modest one and a half months without causing significant worsening in overall patient health.
Estonian: Põhiuuringus pikendas Portrazza lisamine gemtsitabiini ja tsisplatiini sisaldavale keemiaravile patsientide elumust mõnevõrra (pooleteise kuu võrra) patsientide üldtervist oluliselt halvendamata.
English: Portrazza is given as a one hour infusion (drip) into a vein.
Estonian: Portrazzat manustatakse ühetunnise infusioonina (veeni tilgutatava lahusena).
English: There was no improved survival in patients with non-EGFR cancer cells.
Estonian: EGFRita vähirakkudega patsientidel elumus ei pikenenud.
English: The active substance in Portrazza, necitumumab, is a monoclonal antibody (a type of protein) designed to recognise and attach to EGFR on the surface of the cancer cells.
Estonian: Portrazza toimeaine netsitumumaab on monoklonaalne antikeha (teatud tüüpi valk), mis tunneb ära vähirakkude pinnal EGFRi ja seondub sellega.
English: Portrazza is a medicine for treating advanced stages of a type of lung cancer known as squamous nonsmall cell lung cancer.
Estonian: Portrazza on ravim, mis on näidustatud lamerakulise mitteväikerakk-kopsuvähi kaugelearenenud staadiumide raviks.
English: How does Portrazza work?
Estonian: Kuidas Portrazza toimib?
English: Portrazza is available as a concentrate for making a solution and can only be obtained with a prescription.
Estonian: Portrazzat turustatakse infusioonilahuse kontsentraadina ja see on retseptiravim.
English: Portrazza contains the active substance necitumumab.
Estonian: Ravim sisaldab toimeainet netsitumumaabi.
English: Dissolution was evaluated over an 8-hour period.
Estonian: Lahustumist hinnati 8 tunni jooksul.
English: About 20% of the responders reported chronic pain (>6 months).
Estonian: Ligikaudu 20% vastajatest teatas kroonilisest valust (> 6 kuud).
English: Overall summary of the scientific evaluation of Ethirfin and associated names (see Annex I)
Estonian: Ethirfini ja sarnaste nimetuste (vt I lisa) teadusliku hindamise üldkokkuvõte
English: The application was submitted to the reference Member State Denmark and to the concerned Member States (CMS) Germany, Ireland, Italy and the United Kingdom.
Estonian: Taotlus esitati viiteliikmesriigile Taanile ja asjaomastele liikmesriikidele Saksamaale, Iirimaale, Itaaliale ja Ühendkuningriigile.
English: Source; Brennan et al., Addiction 2005; 100 : 777-86
Estonian: Allikas: Brennan et al. Addiction 2005; 100 : 777-86
English: This strength is considered representative for the other (20, 60 and 120 mg) strengths as all strengths are dose proportional and manufactured with the same microgranules.
Estonian: Seda tugevust peetakse muude tugevuste (20, 60 ja 120 mg) suhtes esinduslikuks, sest kõik tugevused on annusega proportsionaalsed ja nende tootmiseks on kasutatud samu mikrograanuleid.
English: Patients being treated with opioids tend to drink less alcohol than patients who do not use opioids at all.
Estonian: Opioididega ravitavad patsiendid kalduvad alkoholi vähem tarbima kui patsiendid, kes opioide üldse ei kasuta.
English: Out of specification results were obtained after 0.25 hours in 20% alcohol, after 0.5 hour in 10% alcohol and after 2 hours in 5% alcohol.
Estonian: Nõuetele mittevastavad tulemused saadi pärast 0,25 tundi 20% alkoholis, 0,5 tundi 10% alkoholis ja 2 tundi 5% alkoholis.
English: The CHMP considered the matter and adopted an Opinion in July 2010 recommending the renewal of the marketing authorisation subject to conditions considered essential to the safe and effective use of the product.
Estonian: Inimravimite komitee arutas küsimust ja võttis 2010. aasta juulis vastu arvamuse, mis soovitas müügiloa pikendamist ravimi ohutuks ja efektiivseks kasutamiseks kindlasti vajalikel tingimustel.
English: The triethylcitrate acts as a plasticizer.
Estonian: Trietüültsitraat toimib plastifikaatorina.
English: Concurrent depression and pain have a much greater impact than either disorder alone and, in patients with pain, depression is associated to more pain sites, greater pain intensity, longer duration of pain, and greater likelihood of poor treatment response (Bair, J et al., Psychosom Med. 2008 October; 70(8): 890-897).
Estonian: Sellele võib kaalu juurde anda asjaolu, et paljudel kroonilise valuga patsientidel on ka depressioon.. Samaaegne depressioon ja valu võivad koos avaldada suuremat mõju kui kumbki eraldi; samuti seostatakse valuga patsientidel depressiooni korral valutavate kohtade arvu suurenemist, intensiivsemat valu, kauem kestvat valu ja suuremat tõenäosust, et valu allub ravile halvasti (Bair, J. et al., Psychosom Med. 2008 October; 70(8): 890-897).
English: Whereas
Estonian: Puudub
English: Germany and the United Kingdom raised potential serious risk to public health concerns due to the dissolution profile of the modified-release product allowing the release of up to 80% of the active substance within 30 minutes, when exposed to 20% alcohol.
Estonian: Saksamaa ja Ühendkuningriik tõstatasid küsimuse võimalikust raskest riskist rahvatervisele toimeainet modifitseeritult vabastava ravimi lahustuvusprofiili tõttu, mille kohaselt vabaneb kokkupuutel 20% alkoholiga 30 minuti jooksul toimeainest kuni 80%.
English: SCIENTIFIC CONCLUSIONS AND GROUNDS FOR NON-RENEWAL OF THE MARKETING AUTHORISATION
Estonian: II LISA TEADUSLIKUD JÄRELDUSED JA MÜÜGILOA PIKENDAMATA JÄTMISE ALUSED
English: It was shown that the dissolution rate increases with increased concentration of ethanol in the dissolution medium.
Estonian: Näidati, et lahustumine oli kiirem, kui lahustumiskeskkonnas oli etanooli kontsentratsioon suurem.
English: If, however, the modified-release system is influenced by an external factor or substance (such as alcohol), it is possible that a large quantity of the active substance is released in a short timeframe so that it resembles an immediate-release dosage form.
Estonian: Kui toimeainet modifitseeritult vabastavat süsteemi mõjutab väline tegur või aine (nt alkohol), on siiski võimalik, et suur toimeainekogus vabaneb lühikese aja jooksul, nii et see meenutab toimeainet kohe vabastavat ravimvormi.
English: In the scientific literature, drinking alcohol is referred as a coping mechanism to deal with the stress associated with pain.
Estonian: Teaduskirjanduses viidatakse alkoholitarbimisele kui valuga seotud stressiga toimetuleku ühele mehhanismile..
English: Dissolution profiles have been performed using the 200 mg capsule strength only.
Estonian: Lahustumisprofiili määramiseks on kasutatud ainult 200 mg kapslit.
English: Grounds for non-renewal of the marketing authorisation
Estonian: Müügiloa pikendamata jätmise alused
English: Both problem drinkers as non-problem drinkers reported to use alcohol to manage pain, although in the latter group to less extent (see figure 1).
Estonian: Uuringus osalesid nii probleemsed kui ka mitteprobleemsed alkoholitarbijad.Nii probleemsed kui ka mitteprobleemsed alkoholitarbijad teatasid, et kasutavad alkoholi valuga toimetulekuks, viimases rühmas siiski väiksemal määral (vt joonis 1).
English: Modified-release products are complex dosage forms designed to release drugs in a controlled manner to achieve desired efficacy and safety profiles.
Estonian: Toimeaine modifitseeritult vabastamine on keerukas annustamisviis, kus toimeaine vabaneb kindlal viisil, et saavutada soovitud efektiivsus- ja ohutusprofiili.
English: • The Committee considered all the data submitted by the MAH,
Estonian: • komitee arutas kõiki müügiloa hoidja esitatud andmeid;
English: The association between chronic pain and alcohol use is summarized in the table below.
Estonian: Seos kroonilise valu ja alkoholi vahel on kokku võetud allolevas tabelis.
English: Ethypharm submitted an application for the renewal, under the mutual recognition procedure, of Ethirfin and associated names, 20mg, 60 mg, 120 mg and 200 mg.
Estonian: Ethypharm esitas taotluse Ethirfini ja sarnaste nimetuste (20 mg, 60 mg, 120 mg ja 200 mg) müügiloa pikendamiseks vastastikuse tunnustamise menetluse kaudu.
English: However, alcohol use is common in patients with chronic pain due to the fact that it reduces pain perception.
Estonian: Alkoholi kasutamine on kroonilise valu all kannatavate patsientide seas siiski sage, sest alkohol vähendab valuaistingut.
English: • The Committee therefore considered that patients exposed to the above mentioned products and concomitant intake of alcohol are at significantly greater risk of developing serious adverse reactions such as respiratory depression and death, and took the view that the risk-benefit balance of the product is not positive under normal conditions of use.
Estonian: • komitee järeldas seega, et patsientidel, kes kasutavad samal ajal ülalmainitud ravimeid ja alkoholi, on märkimisväärselt suurem risk raskete kõrvalnähtude tekkeks, nagu respiratoorne depressioon ja surm, ning võttis seisukoha, et ravimi kasulikkuse ja riski suhe ei ole tavalistel kasutustingimustel positiivne.
English: • A pharmacodynamic interaction between opioid products and alcohol may occur irrespective of the formulation,
Estonian: • farmakodünaamiline koostoime opioide sisaldavate ravimite ja alkoholi vahel võib tekkida ravimvormist sõltumata;
English: The dissolution medium was water, loaded with 5, 10 and 20% ethanol in line with the EMA QWP Q&A document Need for in vitro Dissolution Studies with Alcohol for Modified Release Oral Products Including Opioid Drug Products.
Estonian: Lahustumiskatse vedelikuks oli vesi, millele oli lisatud Euroopa Ravimiameti kvaliteedi töörühma teabedokumendi Need for in vitro Dissolution Studies with Alcohol for Modified Release Oral Products Including Opioid Drug Products järgi 5%, 10% ja 20% etanooli.
English: No in vivo studies have been performed to investigate the effect of alcohol on the absorption of the product.
Estonian: Alkoholi toime uurimiseks ravimi imendumisele ei ole tehtud in vivo uuringuid.
English: The prolonged release properties of this product are ensured by the film coating composed of the polymethacrylate derivative plasticized by triethylcitrate (TEC) to which talc and hydrophobic colloidal silica are added.
Estonian: See koosneb polümetakrülaadi derivaadist, mis on plastifitseeritud trietüültsitraadiga (TEC), millele on lisatud talki ja hüdrofoobset kolloidset ränidioksiidi.